相似文献
1
The Dawning of the Age of Personalized Medicine in Gynecologic Oncology.
Cancers (Basel). 2020 Oct 27;12(11):3135. doi: 10.3390/cancers12113135.
2
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
Surg Oncol Clin N Am. 2020 Jan;29(1):105-113. doi: 10.1016/j.soc.2019.08.008.
3
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
Obstet Gynecol Clin North Am. 2019 Mar;46(1):155-163. doi: 10.1016/j.ogc.2018.09.010.
4
Palliative Care Education in Gynecologic Oncology: a Survey of Gynecologic Oncologists and Gynecologic Oncology Fellows in Thailand.
Asian Pac J Cancer Prev. 2015;16(15):6331-4. doi: 10.7314/apjcp.2015.16.15.6331.
5
Integrating a complementary medicine consultation for women undergoing chemotherapy.
Int J Gynaecol Obstet. 2014 Jan;124(1):51-4. doi: 10.1016/j.ijgo.2013.07.019. Epub 2013 Oct 5.
6
Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital.
J Pers Med. 2021 Dec 21;12(1):3. doi: 10.3390/jpm12010003.
7
Gynecologic Oncology in the Department of Defense.
Semin Reprod Med. 2019 Sep;37(5-06):222-226. doi: 10.1055/s-0040-1709706. Epub 2020 May 1.
8
The dawning era of personalized medicine exposes a gap in medical education.
PLoS Med. 2009 Aug;6(8):e1000138. doi: 10.1371/journal.pmed.1000138. Epub 2009 Aug 25.
9
Personalized oncology: recent advances and future challenges.
Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19.
10
Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.
Gynecol Oncol. 2015 May;137(2):280-4. doi: 10.1016/j.ygyno.2015.02.021. Epub 2015 Feb 28.
引用本文的文献
1
Differences in single gene expression patterns and signaling pathways between Black and White patients in high grade endometrioid endometrial cancer independent of BMI.
Gynecol Oncol Rep. 2024 Mar 6;52:101360. doi: 10.1016/j.gore.2024.101360. eCollection 2024 Apr.
2
Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
Cancers (Basel). 2021 Jun 10;13(12):2901. doi: 10.3390/cancers13122901.
本文引用的文献
1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
2
Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
Curr Treat Options Oncol. 2019 Aug 23;20(10):75. doi: 10.1007/s11864-019-0676-8.
3
PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Jpn J Clin Oncol. 2019 Aug 1;49(8):703-707. doi: 10.1093/jjco/hyz090.
4
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.
5
Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas.
JCO Clin Cancer Inform. 2018 Dec;2:1-16. doi: 10.1200/CCI.17.00096.
6
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
7
Mechanisms of PARP inhibitor sensitivity and resistance.
DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.
8
Endocrine therapy in ovarian cancer: where do we stand?
Curr Opin Obstet Gynecol. 2018 Feb;30(1):17-22. doi: 10.1097/GCO.0000000000000423.
9
Immunotherapy in Gynecologic Cancers: Are We There Yet?
Curr Treat Options Oncol. 2017 Aug 24;18(10):59. doi: 10.1007/s11864-017-0504-y.
10
Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature.
Anticancer Res. 2017 Jun;37(6):2809-2815. doi: 10.21873/anticanres.11631.
Zotero 插件